Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.

This article discusses the use of imiquimod as a treatment for actinic keratosis, basal cell carcinoma, and human papillomavirus warts, noting both its therapeutic benefits and common side effects such as local inflammation and flu-like symptoms.

In a reported case, researchers observed full hair regrowth on the scalp, eyebrows, and eyelashes of a 4-year-old with alopecia universalis after 10 months of treatment with dupilumab, following resistance to baricitinib.

This case report describes a patient with psoriasis who developed alopecia with unique histological features after anti-TNF therapy, suggesting that such effects may require considering treatment suspension for severe cases.

This study reported two cases where infliximab-associated psoriasiform alopecia resolved with significant hair regrowth after stopping infliximab and using potent topical steroid treatment.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.

This study found that imiquimod combined with fish oil in a bigel formulation enhanced antitumor effects and reduced inflammatory side effects in a skin cancer model.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy, suggesting a rare association between the drug and these immune-mediated skin conditions, highlighting the potential benefit of early intervention with baricitinib.

This study found that the MD-3 antibody significantly improved the survival of hair follicle allografts in nonhuman primates by reducing T-cell infiltration.

In this case report, a woman developed severe alopecia areata approximately one year after starting belimumab for systemic lupus erythematosus, with hair loss improving upon discontinuation of the drug, suggesting a possible connection between belimumab and immune-mediated hair loss.

This report describes a rare case of alopecia areata-like psoriasis, associated with skin lesions, following the use of dupilumab in a patient with atopic dermatitis.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This case report describes a patient who developed severe alopecia and a rash after increasing captopril dosage, which resolved upon discontinuing the medication.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This study identified overlapping genetic susceptibility loci in both alopecia areata and inflammatory bowel disease, specifically with Crohn's disease and ulcerative colitis.

This study in mice found that a monoclonal antibody targeting EGFR resulted in skin inflammation mediated by TNFα, suggesting potential pathways for addressing EGFR antibody-induced skin rash in cancer patients.

In this case report, a 23-year-old man with Crohn's disease experienced near-complete resolution of alopecia universalis after 7 months of upadacitinib treatment, suggesting potential benefits for treating concurrent alopecia areata and Crohn's disease.

This article in the International Journal of Dermatology reports on a case series where the drug upadacitinib was used to treat patients with recalcitrant lichen planopilaris, but no abstract or detailed results are provided to assess its efficacy or safety fully.

This case report found that a patient with ritlecitinib-resistant alopecia areata experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential effectiveness and suggesting benefits of personalized treatment strategies targeting the JAK1-mediated pathway.

This study presents a reported case where dupilumab treatment for atopic dermatitis led to improvement in alopecia universalis.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

In this report, a 61-year-old woman with vitiligo showed significant improvement after tofacitinib treatment but developed lung adenocarcinoma, highlighting potential cancer risks associated with JAK inhibitors.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This case report describes a 56-year-old woman with rheumatoid arthritis who developed alopecia universalis during treatment with the TNF inhibitor adalimumab, with no hair regrowth after stopping the medication.

This review discusses the increasing reports of rare cutaneous side effects from topical imiquimod, aiming to inform physicians and dermatologists about its potential adverse effects as its use expands.